m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00427)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
TFRC
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
RNA demethylase ALKBH5 (ALKBH5) [ERASER]
Representative RNA-seq result indicating the expression of this target gene regulated by ALKBH5 | ||
Cell Line | Neutrophils | Mus musculus |
Treatment: Alkbh5-/- neutrophils
Control: Wild type neutrophils
|
GSE198316 | |
Regulation |
|
logFC: -1.41E+00 p-value: 1.41E-09 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | IOX1, which is an inhibitor of ALKBH5, was loaded on HSSS to form HSSS-I, which could effectively ameliorate cardiac dysfunction in acute myocardial infarction. The surface-modified bioengineered ferritin nanocage targeted the dying cells in the infarct area under the guidance of Scarf1. These cells were then phagocytosed through recognition of their Transferrin receptor protein 1 (TFRC) receptor. | |||
Responsed Disease | Acute myocardial infarction | ICD-11: BA41 | ||
Cell Process | Lysosomal escape | |||
In-vivo Model | Wild-type C57 (female, 12-16 weeks old), ALKBH5 /- mice (female and male, 12-16 weeks old), and SPF-grade SD rats (female, 180-230 g) were used to establish the AMI model.Sodium pentobarbital diluted to 10 mg/mL was used to anesthetize the mice or rat at the dose of 50 mg/kg through an intraperitoneal injection. By using a small animal ventilator with endotracheal intubation, thoracotomy was performed at the left fourth intercostal region. The heart was exposed, and the left anterior descending coronary artery (LCA) was occluded through a 6-0 silk suture that was placed 2-3 mm distal to the origin of the LCA with a slipknot. The apical region turned white, and ST segment elevation and T wave inversion of ECG showed that the AMI model was successfully established. Forty-five minutes after ischemia, the slipknot was released, and the ischemic region was reperfused. PBS (0.2 ml), HSSS (23.5 mg/kg, 0.2 ml), IOX1 (10 mg/kg, 0.2 ml), and HSSS-I (33.5 mg/kg, containing 10 mg/kg IOX1, 0.2 ml) were administered through caudal vein injection for 14 days at the frequency of one time per day. | |||
YTH domain-containing family protein 1 (YTHDF1) [READER]
Representative RIP-seq result supporting the interaction between TFRC and the regulator | ||
Cell Line | Hela | Homo sapiens |
Regulation | logFC: 2.40E+00 | GSE63591 |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | YTHDF1 enhanced Transferrin receptor protein 1 (TFRC) expression in HPSCC through an m6A-dependent mechanism. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Hypopharyngeal squamous cell carcinoma | ICD-11: 2B6D.0 | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Cell Process | Ferroptosis | |||
In-vitro Model | YCU-MS861 | Maxillary sinus squamous cell carcinoma | Homo sapiens | CVCL_8021 |
YCU-MS861 | Maxillary sinus squamous cell carcinoma | Homo sapiens | CVCL_8021 | |
FaDu | Hypopharyngeal squamous cell carcinoma | Homo sapiens | CVCL_1218 | |
Detroit 562 | Pharyngeal squamous cell carcinoma | Homo sapiens | CVCL_1171 | |
Hypopharyngeal cancer [ICD-11: 2B6D]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | YTHDF1 enhanced Transferrin receptor protein 1 (TFRC) expression in HPSCC through an m6A-dependent mechanism. | |||
Responsed Disease | Hypopharyngeal squamous cell carcinoma [ICD-11: 2B6D.0] | |||
Target Regulator | YTH domain-containing family protein 1 (YTHDF1) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | Ferroptosis | hsa04216 | ||
Cell Process | Ferroptosis | |||
In-vitro Model | YCU-MS861 | Maxillary sinus squamous cell carcinoma | Homo sapiens | CVCL_8021 |
YCU-MS861 | Maxillary sinus squamous cell carcinoma | Homo sapiens | CVCL_8021 | |
FaDu | Hypopharyngeal squamous cell carcinoma | Homo sapiens | CVCL_1218 | |
Detroit 562 | Pharyngeal squamous cell carcinoma | Homo sapiens | CVCL_1171 | |
Acute myocardial infarction [ICD-11: BA41]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | IOX1, which is an inhibitor of ALKBH5, was loaded on HSSS to form HSSS-I, which could effectively ameliorate cardiac dysfunction in acute myocardial infarction. The surface-modified bioengineered ferritin nanocage targeted the dying cells in the infarct area under the guidance of Scarf1. These cells were then phagocytosed through recognition of their Transferrin receptor protein 1 (TFRC) receptor. | |||
Responsed Disease | Acute myocardial infarction [ICD-11: BA41] | |||
Target Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | ||
Cell Process | Lysosomal escape | |||
In-vivo Model | Wild-type C57 (female, 12-16 weeks old), ALKBH5 /- mice (female and male, 12-16 weeks old), and SPF-grade SD rats (female, 180-230 g) were used to establish the AMI model.Sodium pentobarbital diluted to 10 mg/mL was used to anesthetize the mice or rat at the dose of 50 mg/kg through an intraperitoneal injection. By using a small animal ventilator with endotracheal intubation, thoracotomy was performed at the left fourth intercostal region. The heart was exposed, and the left anterior descending coronary artery (LCA) was occluded through a 6-0 silk suture that was placed 2-3 mm distal to the origin of the LCA with a slipknot. The apical region turned white, and ST segment elevation and T wave inversion of ECG showed that the AMI model was successfully established. Forty-five minutes after ischemia, the slipknot was released, and the ischemic region was reperfused. PBS (0.2 ml), HSSS (23.5 mg/kg, 0.2 ml), IOX1 (10 mg/kg, 0.2 ml), and HSSS-I (33.5 mg/kg, containing 10 mg/kg IOX1, 0.2 ml) were administered through caudal vein injection for 14 days at the frequency of one time per day. | |||
References